| Literature DB >> 29686725 |
Massimo Sartelli1, Gian L Baiocchi2, Salomone Di Saverio3, Francesco Ferrara4, Francesco M Labricciosa5, Luca Ansaloni6, Federico Coccolini6, Deepak Vijayan7, Ashraf Abbas8, Hariscine K Abongwa9, John Agboola10, Adamu Ahmed11, Lali Akhmeteli12, Nezih Akkapulu13, Seckin Akkucuk14, Fatih Altintoprak15, Aurelia L Andreiev7, Dimitrios Anyfantakis16, Boiko Atanasov17, Miklosh Bala18, Dimitrios Balalis19, Oussama Baraket20, Giovanni Bellanova21, Marcelo Beltran22, Renato Bessa Melo23, Roberto Bini24, Konstantinos Bouliaris25, Daniele Brunelli26, Adrian Castillo27, Marco Catani28, Asri Che Jusoh29, Alain Chichom-Mefire30, Gianfranco Cocorullo31, Raul Coimbra32, Elif Colak33, Silvia Costa34, Koray Das35, Samir Delibegovic36, Zaza Demetrashvili37, Isidoro Di Carlo38, Nadezda Kiseleva39, Tamer El Zalabany40, Mario Faro41, Margarida Ferreira42, Gustavo P Fraga43, Mahir Gachabayov44, Wagih M Ghnnam45, Teresa Giménez Maurel46, Georgios Gkiokas47, Carlos A Gomes48, Ewen Griffiths49, Ali Guner50, Sanjay Gupta51, Andreas Hecker52, Elcio S Hirano43, Adrien Hodonou53, Martin Hutan54, Orestis Ioannidis55,56, Arda Isik57, Georgy Ivakhov58, Sumita Jain59, Mantas Jokubauskas60, Aleksandar Karamarkovic61, Saila Kauhanen62, Robin Kaushik51, Alfie Kavalakat63, Jakub Kenig64, Vladimir Khokha65, Desmond Khor66, Dennis Kim27, Jae I Kim67, Victor Kong68, Konstantinos Lasithiotakis69, Pedro Leão70, Miguel Leon71, Andrey Litvin72, Varut Lohsiriwat73, Eudaldo López-Tomassetti Fernandez74, Eftychios Lostoridis75, James Maciel27, Piotr Major76, Ana Dimova77, Dimitrios Manatakis78, Athanasio Marinis79, Aleix Martinez-Perez80, Sanjay Marwah81, Michael McFarlane82,83, Cristian Mesina84, Michał Pędziwiatr102, Nickos Michalopoulos86, Evangelos Misiakos87, Ali Mohamedahmed88, Radu Moldovanu89, Giulia Montori6, Raghuveer Mysore Narayana90, Ionut Negoi91, Ioannis Nikolopoulos92, Giuseppe Novelli93, Viktors Novikovs39, Iyiade Olaoye94, Abdelkarim Omari95, Carlos A Ordoñez96, Mouaqit Ouadii97, Zeynep Ozkan98, Ajay Pal99, Gian M Palini93, Lars I Partecke100, Francesco Pata101, Michał Pędziwiatr102, Gerson A Pereira Júnior103, Tadeja Pintar104, Magdalena Pisarska105, Cesar F Ploneda-Valencia106, Konstantinos Pouggouras75, Vinod Prabhu107, Padmakumar Ramakrishnapillai108, Jean-Marc Regimbeau109, Marianne Reitz110, Daniel Rios-Cruz111, Sten Saar112, Boris Sakakushev113, Charalampos Seretis114, Alexander Sazhin58, Vishal Shelat115, Matej Skrovina116, Dmitry Smirnov117, Charalampos Spyropoulos118, Marcin Strzałka119, Peep Talving112, Ricardo A Teixeira Gonsaga120, George Theobald7, Gia Tomadze121, Myftar Torba122, Cristian Tranà1, Jan Ulrych123, Mustafa Y Uzunoğlu14, Alin Vasilescu124, Savino Occhionorelli125, Aurélien Venara126, Andras Vereczkei127, Nereo Vettoretto128, Nutu Vlad124, Maciej Walędziak129, Tonguç U Yilmaz130, Kuo-Ching Yuan131, Cui Yunfeng132, Justas Zilinskas60, Gérard Grelpois109, Fausto Catena8.
Abstract
Background: Acute appendicitis (AA) is the most common surgical disease, and appendectomy is the treatment of choice in the majority of cases. A correct diagnosis is key for decreasing the negative appendectomy rate. The management can become difficult in case of complicated appendicitis. The aim of this study is to describe the worldwide clinical and diagnostic work-up and management of AA in surgical departments.Entities:
Keywords: Acute appendicitis; Antibiotics; Diagnosis; Management; Surgery
Mesh:
Year: 2018 PMID: 29686725 PMCID: PMC5902943 DOI: 10.1186/s13017-018-0179-0
Source DB: PubMed Journal: World J Emerg Surg ISSN: 1749-7922 Impact factor: 5.469
Clinical and laboratory findings
| Clinical and laboratory findings | Patients |
|---|---|
| Diffuse tenderness | 502 (11.7%) |
| Right lower quadrant pain | 3906 (91.2%) |
| Right lower quadrant tenderness | 2980 (69.6%) |
| Vomiting | 1798 (42.0%) |
| Temperature > 38 °C | 1057 (24.7%) |
| WBC > 10,000/ml | 3494 (81.6%) |
| CRP < 10 mg/l | 848 (19.8%) |
| CRP 10–50 mg/l | 1097 (25.6%) |
| CRP > 50 mg/l | 876 (20.5%) |
| CRP not reported | 1461 (34.1%) |
WBC white blood count, CRP C-reactive protein
Antimicrobial therapy administered during hospitalization in 3463 patients
| Patients receiving antibiotics | |
|---|---|
| Metronidazole or ornidazole | 2021 (58.2%) |
| Third-generation cephalosporins | 1280 (37.0%) |
| Second-generation cephalosporins | 598 (17.2%) |
| Penicillins + beta lactams-inhibitors | 500 (14.4%) |
| First-generation cephalosporins | 437 (12.6%) |
| Second-generation quinolones | 304 (8.8%) |
| Aminoglycosides | 289 (8.3%) |
| Ureidopenicillins + beta lactams-inhibitors | 130 (3.7%) |
| Aminopenicillins | 61 (1.8%) |
| Carbapenems | 58 (1.7%) |
| Third-generation cephalosporins + beta lactams-inhibitors | 52 (1.5%) |
| Third-generation quinolones | 18 (0.5%) |
| Fourth-generation cephalosporins | 12 (0.3%) |
| Others | 15 (0.4%) |
n number of patients receiving antibiotic treatment
Aerobic and anaerobic bacteria identified in 275 swabs of peritoneal fluid
| Total | |
|---|---|
| Aerobic gram-negative bacteria | |
| | 159 (57.8%) |
| | 19 (6.9%) |
| | 4 (1.5%) |
| | 5 (1.8%) |
| | 1 (0.4%) |
| | 5 (1.8%) |
| Aerobic gram-positive bacteria | |
| | 42 (15.3%) |
| | 24 (8.7%) |
| | 11 (4.0%) |
| | 6 (2.2%) |
| Others | 7 (2.5%) |
| Anaerobic bacteria | |
| | 105 (38.2%) |
| | 4 (1.5%) |
n number of specimens collected
Distribution of predictive variables and mortality at univariate analysis
| Variables | Patients | Dead | Survivors | RR (CI 95%) | |
|---|---|---|---|---|---|
| Age > 80 years | 52 (1.2) | 2 (16.7) | 50 (1.2) | 14.23 (3.90–51.96) | < 0.05 |
| Immunosuppression | 71 (1.7) | 3 (25.0) | 68 (1.6) | 15.70 (5.73–43.01) | < 0.001 |
| Severe cardiovascular disease | 154 (3.6) | 3 (25.0) | 151 (3.5) | 7.07 (2.62–19.07) | < 0.05 |
| Charlson Comorbidity Score > 5 | 23 (0.5) | 4 (33.3) | 19 (0.4) | 74.91 (29.93–187.48) | < 0.001 |
| Previous episodes suspected app. | 427 (10.0) | 2 (16.7) | 425 (10.0) | 1.67 (0.47–5.95) | 0.33 |
| Previous antimicrobial therapy | 327 (7.6) | 4 (33.3) | 323 (7.6) | 4.40 (1.97–9.87) | < 0.05 |
| WBC > 10,000/ml | 3434 (80.2) | 10 (83.3) | 3424 (80.2) | 1.04 (0.81–1.33) | 1.00 |
| CRP > 50 mg/l | 876 (20.5) | 5 (41.7) | 871 (20.4) | 2.04 (1.04–4.00) | 0.08 |
| WSES Grading System | |||||
| Grade 0 | 145 (3.4) | 0 | 144 (3.4) | 0 | 1.00 |
| Stage 1 | 1896 (44.3) | 3 (25.0) | 1893 (44.3) | 0.56 (0.21–1.50) | 0.18a |
| Stage 2a | 632 (14.8) | 0 | 632 (14.8) | 0 | 0.23 |
| Stage 2b | 129 (3.0) | 1 (8.3) | 128 (3.0) | 2.78 (0.42–18.29) | 0.31 |
| Stage 3a | 332 (7.8) | 0 | 332 (7.8) | 0 | 0.62 |
| Stage 3b | 181 (4.2) | 0 | 181 (4.2) | 0 | 1.00 |
| Stage 3c | 73 (1.7) | 2 (16.7) | 71 (1.7) | 10.02 (2.77–36.27) | < 0.05 |
| Stage 4 | 376 (8.8) | 6 (50.0) | 370 (8.7) | 5.75 (3.24–10.22) | < 0.001 |
| Not reported | 517 (12.1) | 0 | 517 (12.1) | NA | NA |
| Pathology | |||||
| Normal | 144 (3.4) | 0 | 144 (3.4) | 0 | 1.00 |
| Inflammation | 1147 (26.8) | 2 (16.7) | 1145 (26.8) | 0.62 (0.17–2.20) | 0.53 |
| Periappendicitis | 236 (5.5) | 1 (8.3) | 235 (5.5) | 1.51 (0.23–9.92) | 0.49 |
| Suppurative | 1176 (27.5) | 2 (16.7) | 1174 (27.5) | 0.61 (0.17–2.15) | 0.53 |
| Gangrenous | 673 (15.7) | 2 (16.7) | 671 (15.7) | 1.06 (0.30–3.76) | 1.00 |
| Perforation | 256 (6.0) | 4 (33.3) | 252 (5.9) | 5.65 (2.51–12.68) | < 0.05 |
| Not reported | 650 (15.2) | 1 (8.3) | 650 (15.2) | NA | NA |
All p values calculated using two-sided Fisher’s exact test unless otherwise noted
RR risk ratio, CI confidence interval, NA not applicable
aTwo-sided chi-square test
Results of multinomial logistic regression for the analysis of variables associated with mortality
| Variables | OR | 95% CI | |
|---|---|---|---|
| Age > 80 | 4.54 | 0.59–35.20 | 0.15 |
| Immunosuppression | 1.17 | 0.11–12.63 | 0.90 |
| Severe cardiovascular disease | 1.51 | 0.25–9.08 | 0.65 |
| Charlson Comorbidity Score > 5 | 52.45 | 5.95–462.03 | < 0.05 |
| Previous antimicrobial therapy | 2.29 | 0.48–10.85 | 0.30 |
| WSES Grading System | |||
| Stage 3c | 11.77 | 1.37–100.78 | < 0.05 |
| Stage 4 | 11.32 | 2.18–58.62 | < 0.05 |
| Pathology | |||
| Perforation | 1.43 | 0.28–7.24 | 0.66 |
CI confidence interval, OR odds ratio